Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral nerve stimulation & intrathecal pumps cases in Arkansas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (174 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 11 | 678 | 29% |
| 2020 | 13 | 571 | 32% |
| 2021 | 9 | 710 | 37% |
| 2022 | 18 | 784 | 40% |
| 2023 | 14 | 782 | 46% |
| 2024 | 21 | 852 | 49% |
| 2025 from claims | – | 769 622–903 | 50% |
| 2026 forecast | – | 808 633–1,014 | 51% |
| 2027 forecast | – | 848 629–1,121 | 51% |
| 2028 forecast | – | 891 631–1,230 | 52% |
| 2029 forecast | – | 935 636–1,341 | 53% |
| 2030 forecast | – | 982 643–1,457 | 53% |
PNS lead and generator, intrathecal pump and catheter. Professional codes (what the surgeon bills): CPT 64555, 64590, 62362, 62350.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 76% of the cases CMS names in Arkansas; 12 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 7% inpatient hospital, 37% hospital outpatient, 54% surgery center, 2% office. The share outside the hospital has moved +10 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center | Office |
|---|---|---|---|---|
| 2026 · ~810 | ~54 | ~280 | ~460 | ~16 |
| 2027 · ~850 | ~57 | ~280 | ~490 | ~16 |
| 2028 · ~890 | ~60 | ~290 | ~520 | ~16 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 59% (54% in 2025), hospital outpatient about 33% (37% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 60 | 4,698+15%/yr | +15%/yr | 2.0 | 72% | 9,310 in 2030+12%/yr |
| Florida | 65 | 3,941+8.8%/yr | +8.8%/yr | 1.6 | 74% | 5,860 in 2030+6.8%/yr |
| Georgia | 20 | 1,195+14%/yr | +14%/yr | 1.3 | 62% | 2,360 in 2030+12%/yr |
| North Carolina | 21 | 1,154+13%/yr | +13%/yr | 1.1 | 42% | 1,560 in 2030+5.2%/yr |
| Tennessee | 23 | 1,041+6.2%/yr | +6.2%/yr | 1.4 | 47% | 2,170 in 2030+13%/yr |
| Oklahoma | 21 | 1,024+2.9%/yr | +2.9%/yr | 2.0 | 28% | 1,160 in 2030+2.1%/yr |
| South Carolina | 17 | 936+18%/yr | +18%/yr | 1.3 | 42% | 2,480 in 2030+18%/yr |
| Kentucky | 14 | 792+1.1%/yr | +1.1%/yr | 1.6 | 17% | 700 in 2030−2%/yr |
| Maryland | 12 | 704+23%/yr | +23%/yr | 0.8 | 89% | 1,180 in 2030+9%/yr |
| Virginia | 13 | 571−0.7%/yr | −0.7%/yr | 0.5 | 30% | 670 in 2030+2.7%/yr |
| Mississippi | 13 | 445+2.3%/yr | +2.3%/yr | 1.1 | 76% | 590 in 2030+4.7%/yr |
| Louisiana | 4 | 441+6.5%/yr | +6.5%/yr | 1.0 | 46% | 410 in 2030−1.4%/yr |
| Alabama | 6 | 319+4.8%/yr | +4.8%/yr | 0.7 | 49% | 670 in 2030+13%/yr |
| West Virginia | 3 | 158+6.2%/yr | +6.2%/yr | 0.7 | 27% | 100 in 2030−7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 73 | 7,188−5.6%/yr | −5.6%/yr | 18.31.3× | 76% | 7,600 in 2030+0.9%/yr |
| Spinal cord & DRG stimulation | 11 | 302−2.5%/yr | −2.5%/yr | 0.70.8× | 51% | 330 in 2030+1.3%/yr |
Peripheral nerve stimulation & intrathecal pumps in every state, and its device makers · Every procedure market in Arkansas · Every state · Compare with Texas
Spr Therapeutics leads with 68% of company spending on these surgeons in 2025, +54 pts on 2024.
In 2025, 6 companies reported engagement with Arkansas’s surgeons worth $40K in consulting, speaking, meals and travel tied to these products, about $1,885 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.